Ítems similars: Pfizer Case Study: Protecting Blockbuster Drugs from Generic Competition
- Bristol-Myers Squibb Case Study: Overcoming the threat from generic Antidiabetics
- Aliskirin Case Study: Will Aliskiren Live Up to the Hype & Achieve Blockbuster Status?
- Pfizer's Maraviroc Case Study: Maraviroc is Close to Approval, Despite Hurdles Along the Way
- Prevnar: the First Vaccine Blockbuster
- Amgen Case Study: Protecting Epogen from Competition
- Black Book - Pfizer Incorporated (1973)